Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Can-Fite BioPharma stock
Learn how to easily invest in Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Can-Fite BioPharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CANF – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Can-Fite BioPharma stock price (NYSE MKT: CANF)Use our graph to track the performance of CANF stocks over time.
Can-Fite BioPharma shares at a glance
|Latest market close||$1.31|
|52-week range||$0.94 - $3.07|
|50-day moving average||$1.30|
|200-day moving average||$1.84|
|Wall St. target price||$6.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.69|
Buy Can-Fite BioPharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Can-Fite BioPharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Can-Fite BioPharma price performance over time
|1 week (2022-01-07)||2.34%|
|1 month (2021-12-17)||3.15%|
|3 months (2021-10-15)||-15.48%|
|6 months (2021-07-16)||-43.29%|
|1 year (2021-01-15)||-31.05%|
|2 years (2020-01-16)||-52.36%|
|3 years (2019-01-16)||1.55%|
|5 years (2017-01-13)||2.36|
Can-Fite BioPharma financials
|Gross profit TTM||$763,000|
|Return on assets TTM||-55.28%|
|Return on equity TTM||-128.53%|
|Market capitalisation||$27.4 million|
TTM: trailing 12 months
Can-Fite BioPharma share dividends
We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.
Have Can-Fite BioPharma's shares ever split?
Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.
Can-Fite BioPharma share price volatility
Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $0.9402 up to $3.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6889. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Can-Fite BioPharma overview
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Can-Fite BioPharma in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
Frequently asked questionsWhat percentage of Can-Fite BioPharma is owned by institutions?
Currently 8.212% of Can-Fite BioPharma shares are held by institutions. How many people work for Can-Fite BioPharma?
Latest data suggests 8 work at Can-Fite BioPharma. When does the fiscal year end for Can-Fite BioPharma?
Can-Fite BioPharma's fiscal year ends in December. Where is Can-Fite BioPharma based?
Can-Fite BioPharma's address is: 10 Bareket Street, Petah Tikva, Israel, 4951778 What is Can-Fite BioPharma's ISIN number?
Can-Fite BioPharma's international securities identification number is: US13471N2018 What is Can-Fite BioPharma's CUSIP number?
Can-Fite BioPharma's Committee on Uniform Securities Identification Procedures number is: 13471N102
More guides on Finder
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert